Difficulty Swallowing: Drugs That Cause or Treat It

What Is Dysphagia and Why Does It Matter?

Dysphagia is the medical term for difficulty swallowing. The sensation can range from a mild awareness that food is moving slowly to a complete inability to pass solid food or liquids. Epidemiological data from a population-based U.S. Survey found that 33.7% of respondents aged 50 and older reported at least occasional swallowing difficulty, and 6.7% reported symptoms on more than half of eating occasions. [1]

Clinically, dysphagia is split into two distinct categories, and confusing them leads to delayed diagnoses.

Oropharyngeal Dysphagia

Oropharyngeal dysphagia arises from problems in the mouth, pharynx, or upper esophageal sphincter. Patients typically report coughing, choking, nasal regurgitation, or the sense that food "won't go down" within one second of swallowing. Neurological conditions such as stroke, Parkinson disease, and amyotrophic lateral sclerosis account for a large share of cases. A 2020 systematic review in the BMJ found that post-stroke dysphagia occurs in approximately 50% of acute stroke patients, with aspiration pneumonia following in up to 35% of those cases. [2]

Esophageal Dysphagia

Esophageal dysphagia originates below the upper esophageal sphincter and is felt as food sticking in the mid-chest or lower sternal area. Structural causes (stricture, ring, tumor) tend to cause dysphagia only to solids initially. Motility disorders such as achalasia cause dysphagia to both solids and liquids from the outset.

Drugs That Cause Difficulty Swallowing

A wide range of medications cause or worsen dysphagia through four main mechanisms: direct mucosal injury, reduced lower esophageal sphincter (LES) tone, impaired salivary flow (xerostomia), or central/peripheral neuromuscular suppression.

Pill Esophagitis: Direct Mucosal Damage

Pill esophagitis is the most preventable drug-related swallowing problem. Tablets or capsules that lodge at the level of the aortic arch (the most common anatomical hold-up point) release caustic contents locally, producing ulceration, odynophagia (painful swallowing), and sometimes stricture formation. [3]

The highest-risk agents include:

• Bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly). Alendronate carries an FDA black-box warning for severe esophageal reactions. Patients must remain upright for at least 30 minutes and take the tablet with a full 240 mL (8 oz) glass of water. [4]
• Doxycycline and tetracycline antibiotics. A retrospective endoscopic series found doxycycline responsible for roughly 20% of pill esophagitis cases.
• NSAIDs and aspirin (e.g., ibuprofen 400 to 800 mg, naproxen 500 mg). These inhibit prostaglandin synthesis in the mucosa, reducing its resistance to acid injury.
• Potassium chloride extended-release tablets. Older wax-matrix formulations caused notable rates of mid-esophageal ulceration in trials from the 1980s.
• Iron sulfate (ferrous sulfate 325 mg). The low pH of dissolved iron is directly corrosive to esophageal epithelium.
• Quinidine and other antiarrhythmics. Quinidine produces deep ulcers and occasionally stricture.
• Clindamycin 300 mg capsules. Small capsules resist saliva dissolution and can produce rapid-onset retrosternal pain within hours of ingestion.

A 2019 review in the American Journal of Gastroenterology calculated that pill-induced esophageal injury accounts for approximately 1 in every 10,000 hospital admissions annually in the United States. [5]

Medications That Reduce LES Tone and Worsen Reflux

When the LES stays chronically weak, acid and pepsin reflux into the esophagus, provoking esophagitis, peptic stricture, and ultimately dysphagia. Several drug classes are directly implicated:

• Calcium channel blockers (amlodipine, nifedipine, diltiazem). These relax smooth muscle throughout the esophagus, reducing both LES pressure and esophageal peristaltic amplitude.
• Nitrates (isosorbide mononitrate, nitroglycerin). Used for angina, these lower LES pressure as a direct pharmacodynamic effect.
• Benzodiazepines (diazepam, clonazepam). Reduce LES tone and blunt the cough reflex, increasing aspiration risk.
• Tricyclic antidepressants (amitriptyline, nortriptyline). Anticholinergic activity slows esophageal transit and reduces LES pressure.
• Theophylline. Bronchodilator that relaxes LES smooth muscle; now less commonly used, but still prescribed for refractory COPD.
• Progesterone-containing hormonal contraceptives. Progesterone relaxes smooth muscle, and a prospective study found that oral contraceptive users had measurably lower LES pressures compared with hormone-free controls. [6]

Anticholinergic and Antipsychotic Drugs

Drugs with strong anticholinergic profiles reduce saliva production, impair pharyngeal muscle coordination, and slow esophageal clearance. Antipsychotics carry the added risk of drug-induced parkinsonism and tardive dyskinesia, both of which disrupt the swallowing sequence.

Agents most often implicated:

• First-generation antipsychotics (haloperidol, chlorpromazine). Tardive dyskinesia of the tongue and pharynx directly disrupts the oral phase of swallowing.
• Second-generation antipsychotics (clozapine, olanzapine). Clozapine causes sialorrhea paradoxically (excess saliva due to cholinomimetic M4 agonism), yet simultaneously impairs swallowing coordination. A 2021 case series in Schizophrenia Research documented aspiration pneumonia in 3.4% of clozapine-treated patients over 12 months. [7]
• Opioids (oxycodone, morphine, fentanyl). Suppress the cough reflex and slow upper esophageal sphincter relaxation latency, increasing both aspiration and residue.
• Antihistamines (diphenhydramine 25 to 50 mg). Drying of secretions and sedation combine to impair safe swallowing.

GLP-1 Receptor Agonists and Swallowing

This is a clinically active area of interest. GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) slow gastric emptying and have been reported to reduce esophageal motility in case series. The FAERS (FDA Adverse Event Reporting System) database contains a growing number of reports of dysphagia associated with semaglutide use, though causality has not been established in a randomized trial as of early 2025. [8]

The HealthRX clinical team uses a four-question screen for any GLP-1 patient reporting new swallowing symptoms:

1. Does the symptom occur with solids only, or with liquids as well?
2. Did symptoms begin or worsen within 4 weeks of a GLP-1 dose increase?
3. Is there associated heartburn, regurgitation, or nausea?
4. Is there any weight loss beyond that expected from the GLP-1 regimen?

A "yes" to question 4 warrants upper endoscopy regardless of the other answers, as esophageal or gastric malignancy must be excluded.

Drugs That Treat Difficulty Swallowing

Treatment selection depends entirely on the mechanism. A peptic stricture needs dilation plus acid suppression; a motility disorder needs a different approach entirely.

Proton Pump Inhibitors (PPIs)

PPIs are the cornerstone of treatment for GERD-related dysphagia and peptic esophageal strictures. By suppressing parietal cell H+/K+-ATPase, they reduce acid exposure by 85 to 95% over 24 hours. [9]

Standard dosing for dysphagia from erosive esophagitis:

• Omeprazole 20 to 40 mg orally once daily before breakfast
• Pantoprazole 40 mg orally once daily
• Esomeprazole 40 mg orally once daily for 4 to 8 weeks, then maintenance at the lowest effective dose

A Cochrane meta-analysis of 12 trials (N=2,896) found PPIs superior to H2-receptor antagonists for healing erosive esophagitis at 8 weeks (relative risk of healing 1.33, 95% CI 1.24 to 1.44). [10]

Botulinum Toxin Injections

For achalasia and other spastic esophageal motility disorders, endoscopic injection of botulinum toxin A (Botox) 80 to 100 units into the lower esophageal sphincter provides symptomatic relief in roughly 70 to 80% of patients at 1 month. Relapse occurs in 50% by 6 to 12 months, making it best suited for patients who are poor surgical candidates. [11]

Pneumatic Dilation

Controlled balloon dilation of the LES under fluoroscopic or endoscopic guidance is a standard treatment for achalasia. The European Society of Gastrointestinal Endoscopy (ESGE) recommends graded pneumatic dilation starting with a 30 mm balloon, with reported 5-year remission rates of approximately 58%. [12]

Surgical and Endoscopic Options

• Heller myotomy (laparoscopic). Division of the LES circular muscle fibers combined with partial fundoplication. The POEM (per-oral endoscopic myotomy) procedure achieves similar 2-year success rates (90 to 95%) with shorter hospitalization. [13]
• Esophageal dilation (bougie or balloon). First-line for benign peptic strictures. Typically requires a series of 2 to 3 sessions. Recurrence is common without concurrent PPI therapy.
• Esophageal stenting. Reserved for malignant strictures or refractory benign strictures; self-expanding metal stents provide palliation in esophageal cancer patients with a median improvement in dysphagia score sustained for 4 to 6 months.

Swallowing Therapy and Speech-Language Pathology

For oropharyngeal dysphagia, particularly post-stroke or neurodegenerative causes, exercise-based dysphagia therapy directed by a speech-language pathologist (SLP) remains a primary intervention. A randomized trial (N=306) published in Lancet Neurology demonstrated that intensive swallowing rehabilitation reduced aspiration pneumonia rates at 6 months compared with standard care (11% vs. 20%, P<0.01). [14]

Specific techniques include the Mendelsohn maneuver, supraglottic swallow, effortful swallow, and the Shaker head-lift exercise, which targets the suprahyoid muscle group.

Neostigmine and Cholinergic Agents

For patients with dysphagia secondary to myasthenia gravis, pyridostigmine bromide (Mestinon) 30 to 60 mg three to four times daily is standard of care. It inhibits acetylcholinesterase at the neuromuscular junction, improving voluntary muscle function throughout the swallowing mechanism. The American Academy of Neurology endorses pyridostigmine as first-line symptomatic therapy for myasthenia. [15]

Calcium Channel Blockers in Spastic Disorders

Paradoxically, while calcium channel blockers worsen GERD-related dysphagia, they are also used to reduce esophageal spasm in diffuse esophageal spasm (DES) and hypercontractile (jackhammer) esophagus. Diltiazem 60 to 90 mg four times daily or nifedipine 10 to 20 mg 30 minutes before meals reduces the amplitude of high-pressure esophageal contractions by 30 to 40% in small crossover trials. [16]

Tricyclic Antidepressants in Functional Dysphagia

Low-dose tricyclic antidepressants, particularly amitriptyline 10 to 25 mg at bedtime, reduce esophageal visceral hypersensitivity in patients with functional dysphagia (esophageal hypersensitivity without structural or motility abnormality). The ACG 2022 guidelines give a conditional recommendation for this approach based on extrapolation from functional esophageal disorder data.

Diagnosing Drug-Related Dysphagia

Taking the Drug History

Every patient presenting with dysphagia should have a complete medication reconciliation performed, including OTC supplements. The temporal relationship between starting or dose-escalating a drug and symptom onset is the single most diagnostically useful piece of information. Ask specifically about tablet size, whether the patient takes medications at bedtime (lying flat), and fluid volume consumed at dosing.

Endoscopy

Upper endoscopy (esophagogastroduodenoscopy, EGD) is the gold-standard test for esophageal dysphagia. It identifies mucosal lesions, strictures, rings, eosinophilic esophagitis (EoE), and malignancy. The ACG recommends EGD as the first-line evaluation in adult patients with new dysphagia, particularly when alarm symptoms are present. [17]

Barium Esophagram

A timed barium esophagram (100 mL of low-density barium, column height measured at 1, 2, and 5 minutes) is the preferred screening test for achalasia and motility disorders. It also detects Zenker diverticulum and extrinsic compression missed at endoscopy.

High-Resolution Esophageal Manometry

High-resolution manometry (HRM) with the Chicago Classification v4.0 (2021) is required to formally categorize esophageal motility disorders. Chicago Classification v4.0 separates disorders into three tiers: absent peristalsis, major motility disorders (achalasia subtypes I, III, EGJ outflow obstruction), and minor motility disorders. [18]

When to Seek Urgent Evaluation

See a clinician the same week for any of the following:

• Progressive dysphagia to solids over 4 to 8 weeks, especially with unintentional weight loss
• Dysphagia accompanied by hematemesis or melena
• Odynophagia (pain on swallowing) without an obvious pill esophagitis explanation
• New dysphagia in a patient with a history of head and neck cancer or Barrett esophagus
• Complete inability to swallow liquids (this constitutes an emergency, and same-day endoscopy is warranted)

The American Gastroenterological Association's 2023 clinical care pathway states: "Dysphagia in adults should be presumed to have a structural or serious mucosal cause until proven otherwise by endoscopic evaluation." [17]

Practical Drug-Specific Recommendations

| Drug Class | Dysphagia Mechanism | Mitigation Strategy | |---|---|---| | Bisphosphonates | Direct mucosal injury | Take sitting upright, 240 mL water, 30-min post-dose upright period | | Doxycycline | Direct mucosal injury | Take with full glass of water; avoid bedtime dosing | | NSAIDs | Prostaglandin inhibition | Take with food; consider PPI co-prescription | | Calcium channel blockers | LES relaxation | Time dose away from meals; consider alternative antihypertensive | | Antipsychotics | Drug-induced parkinsonism, tardive dyskinesia | Lowest effective dose; consider SLP evaluation | | Opioids | Suppressed UES relaxation, cough reflex | Modified texture diet; SLP assessment | | GLP-1 agonists | Delayed gastric emptying, possible esophageal effects | Screen with 4-question tool; EGD if unexplained weight loss | | Iron sulfate | Low-pH mucosal injury | Take with 120 mL water; ferric formulations (ferric maltol) may be better tolerated |